Medtide Quick Ratio

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.